Rapport Therapeutics's top three insider shareholders as of July 24, 2026 are Rock Ventures V, L.P. Third (TenPercentOwner, 6.71Mn shares), Venture Partners Xii, Llc Arch (TenPercentOwner, 3.73Mn shares), James Healy (Director, 1.88Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Steven M Paul | - | 0 | 41,666 | 15 Sep, 2025 |
| James Healy | - | 0 | 1,881,968 | 10 Jun, 2024 |
| Troy A. Ignelzi | Chief Financial Officer | 10,000 | 0 | 13 Mar, 2025 |
| Reid M Huber | - | 20,400 | 0 | 15 Sep, 2025 |
| Abraham Ceesay | Chief Executive Officer | 556,247 | 20,729 | 19 Feb, 2026 |
| Rock Ventures V, L.P. Third | - | 6,709,228 | 0 | 21 Apr, 2026 |
| Cheryl Gault | Chief Operating Officer | 159,914 | 0 | 31 Mar, 2026 |
| Venture Partners Xii, Llc Arch | - | 0 | 3,728,738 | 10 Jun, 2024 |
| David Bredt | Chief Scientific Officer | 393,075 | 0 | 19 Feb, 2026 |
| Krishnaswamy Yeleswaram | Chief Development Officer | 266,651 | 0 | 14 Apr, 2026 |
| Wendy B. Young | - | 9,500 | 0 | 11 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Apr, 2026 | Rock Ventures V, L.P. Third | Common Stock | D | 426,005 | $40.32 | 6,709,228 | D | S |
| 17 Apr, 2026 | Rock Ventures V, L.P. Third | Common Stock | D | 426,005 | $40.32 | 6,709,228 | D | S |
| 17 Apr, 2026 | Rock Ventures V, L.P. Third | Common Stock | D | 426,005 | $40.32 | 6,709,228 | D | S |
| 10 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 500 | $34.98 | 286,016 | D | S |
| 13 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 9,165 | $34.97 | 276,851 | D | S |
| 14 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 10,200 | $35.08 | 266,651 | D | S |
| 08 Apr, 2026 | Krishnaswamy Yeleswaram | Common Stock | D | 360 | $34.90 | 286,516 | D | S |
| 30 Mar, 2026 | Cheryl Gault | Common Stock | D | 7,161 | $28.04 | 162,753 | D | S |
| 30 Mar, 2026 | Cheryl Gault | Common Stock | D | 2,839 | $28.55 | 159,914 | D | S |
| 05 Mar, 2026 | Cheryl Gault | Common Stock | D | 2,014 | $28.93 | 169,914 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 3,552 | $29.05 | 558,528 | D | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 900 | $28.02 | 394,675 | D | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 5,400 | $28.95 | 389,275 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,281 | $29.80 | 556,247 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,983 | $29.04 | 22,829 | I | S |
| 17 Feb, 2026 | David Bredt | Common Stock | D | 2,200 | $29.59 | 387,075 | D | S |
| 18 Feb, 2026 | Abraham Ceesay | Common Stock | D | 2,100 | $29.80 | 20,729 | I | S |
| 19 Feb, 2026 | David Bredt | Common Stock | A | 6,000 | $1.80 | 393,075 | D | M |
| 19 Feb, 2026 | David Bredt | Stock Options (Right to Buy) | D | 6,000 | $0.00 | 88,080 | D | M |
| 02 Feb, 2026 | Cheryl Gault | Stock Option (Right to Buy) | A | 132,000 | $0.00 | 132,000 | D | A |